

Stefania Cheli

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3754156/publications.pdf>

Version: 2024-02-01

34
papers

397
citations

932766
10
h-index

794141
19
g-index

34
all docs

34
docs citations

34
times ranked

752
citing authors

| # | ARTICLE | IF | CITATIONS |
|----|---|-----|-----------|
| 1 | Remodeling of the chromatin structure of the facioscapulohumeral muscular dystrophy (FSHD) locus and upregulation of FSHD-related gene 1 (FRG1) expression during human myogenic differentiation. <i>BMC Biology</i> , 2009, 7, 41. | 1.7 | 81 |
| 2 | DPD and UGT1A1 deficiency in colorectal cancer patients receiving triplet chemotherapy with fluoropyrimidines, oxaliplatin and irinotecan. <i>British Journal of Clinical Pharmacology</i> , 2015, 80, 581-588. | 1.1 | 52 |
| 3 | Expression Profiling of FSHD-1 and FSHD-2 Cells during Myogenic Differentiation Evidences Common and Distinctive Gene Dysregulation Patterns. <i>PLoS ONE</i> , 2011, 6, e20966. | 1.1 | 39 |
| 4 | Levofloxacin-induced seizures in a patient without predisposing risk factors: the impact of pharmacogenetics. <i>European Journal of Clinical Pharmacology</i> , 2013, 69, 1611-1613. | 0.8 | 17 |
| 5 | Pharmacokinetics and Pharmacogenetics of Selective Serotonin Reuptake Inhibitors During Pregnancy: An Observational Study. <i>Therapeutic Drug Monitoring</i> , 2017, 39, 197-201. | 1.0 | 17 |
| 6 | Neonatal Outcomes in Maternal Depression in Relation to Intrauterine Drug Exposure. <i>Frontiers in Pediatrics</i> , 2019, 7, 309. | 0.9 | 16 |
| 7 | Is a pharmacogenomic panel useful to estimate the risk of oxaliplatin-related neurotoxicity in colorectal cancer patients?. <i>Pharmacogenomics Journal</i> , 2019, 19, 465-472. | 0.9 | 16 |
| 8 | The first steps towards the era of personalised vaccinology: predicting adverse reactions. <i>Pharmacogenomics Journal</i> , 2015, 15, 284-287. | 0.9 | 14 |
| 9 | Clinical and genetic factors associated with increased risk of severe liver toxicity in a monocentric cohort of HIV positive patients receiving nevirapine-based antiretroviral therapy. <i>BMC Infectious Diseases</i> , 2018, 18, 556. | 1.3 | 14 |
| 10 | Undetected Toxicity Risk in Pharmacogenetic Testing for Dihydropyrimidine Dehydrogenase. <i>International Journal of Molecular Sciences</i> , 2015, 16, 8884-8895. | 1.8 | 13 |
| 11 | The role of Toll-like receptor 4 polymorphisms in vaccine immune response. <i>Pharmacogenomics Journal</i> , 2016, 16, 96-101. | 0.9 | 12 |
| 12 | Clinical and genetic determinants of nevirapine plasma trough concentration. <i>SAGE Open Medicine</i> , 2018, 6, 205031211878086. | 0.7 | 11 |
| 13 | Variant alleles in factor V, prothrombin, plasminogen activator inhibitor-1, methylenetetrahydrofolate reductase and risk of thromboembolism in metastatic colorectal cancer patients treated with first-line chemotherapy plus bevacizumab. <i>Pharmacogenomics Journal</i> , 2017, 17, 331-336. | 0.9 | 10 |
| 14 | SLC29A1 polymorphism and prediction of anaemia severity in patients with chronic hepatitis C receiving triple therapy with telaprevir. <i>Journal of Antimicrobial Chemotherapy</i> , 2015, 70, 1155-1160. | 1.3 | 9 |
| 15 | Therapeutic drug monitoring and pharmacogenetics of antipsychotics and antidepressants in real life settings: A 5-year single centre experience. <i>World Journal of Biological Psychiatry</i> , 2021, 22, 34-45. | 1.3 | 9 |
| 16 | Renal function in <sc>HIV</sc>/<sc>HBV</sc> coâ€infecte and <sc>HBV</sc> monoâ€infecte patients on a longâ€term treatment with tenofovir in real life setting. <i>Clinical and Experimental Pharmacology and Physiology</i> , 2017, 44, 191-196. | 0.9 | 8 |
| 17 | ABCB1 c.3435C>T polymorphism is associated with platinum toxicity: a preliminary study. <i>Cancer Chemotherapy and Pharmacology</i> , 2019, 83, 803-808. | 1.1 | 8 |
| 18 | ABCC4 single-nucleotide polymorphisms as markers of tenofovir disoproxil fumarate-induced kidney impairment. <i>Pharmacogenomics Journal</i> , 2021, 21, 586-593. | 0.9 | 8 |

| # | ARTICLE | IF | CITATIONS |
|----|---|-----|-----------|
| 19 | In linezolid underexposure, pharmacogenetics matters: The role of CYP3A5. <i>Biomedicine and Pharmacotherapy</i> , 2021, 139, 111631. | 2.5 | 8 |
| 20 | LightSNiP assay is a good strategy for pharmacogenetics test. <i>Frontiers in Pharmacology</i> , 2015, 6, 114. | 1.6 | 5 |
| 21 | Pharmacogenetic approach to losartan in Marfan patients: a starting point to improve dosing regimen?. <i>Drug Metabolism and Personalized Therapy</i> , 2016, 31, 157-163. | 0.3 | 5 |
| 22 | ACE inhibitors and ribavirin-associated cough: a common undefined predisposing factor?. <i>European Journal of Clinical Pharmacology</i> , 2013, 69, 743-745. | 0.8 | 4 |
| 23 | Predictive testing for DPD deficiency in a patient with familial history of fluoropyrimidine-associated toxicity. <i>Personalized Medicine</i> , 2014, 11, 259-262. | 0.8 | 4 |
| 24 | Pharmacogenetic variants in bipolar disorder with elevated treatment resistance and intolerance: Towards a personalized pattern of care. <i>Bipolar Disorders</i> , 2019, 21, 288-291. | 1.1 | 4 |
| 25 | Different effects of glucocorticoids on darunavir plasma concentrations. <i>European Journal of Clinical Pharmacology</i> , 2019, 75, 733-735. | 0.8 | 3 |
| 26 | Fast clearance of anti-TNF \pm agents unrelated to antidrug antibodies: a case report. <i>European Journal of Clinical Pharmacology</i> , 2022, 78, 891-893. | 0.8 | 3 |
| 27 | <i>ITPA</i> and <i>SLC29A1</i> Genotyping for the Prediction of Ribavirin Dose Reduction in Anti-HCV Triple Therapy with Protease Inhibitors. <i>Pharmacology</i> , 2015, 96, 163-166. | 0.9 | 2 |
| 28 | Single nucleotide polymorphisms to predict taxanes toxicities and effectiveness in cancer patients. <i>Pharmacogenomics Journal</i> , 2021, 21, 491-497. | 0.9 | 2 |
| 29 | Case of Suboptimal Linezolid Exposure: Is There a Role for Pharmacogenetics?. <i>Therapeutic Drug Monitoring</i> , 2020, 42, 347-348. | 1.0 | 2 |
| 30 | Fluoropyrimidine-Associated Toxicity in Two Gastrointestinal Cancer Patients: Potential Role of Common DPYD Polymorphisms. <i>Chemotherapy</i> , 2017, 62, 323-326. | 0.8 | 1 |
| 31 | Pharmacogenetics-based optimisation of atazanavir treatment: potential role of new genetic predictors. <i>Drug Metabolism and Personalized Therapy</i> , 2017, 32, 115-117. | 0.3 | 0 |
| 32 | HLA-B*57. <i>Pharmacogenetics and Genomics</i> , 2017, 27, 81-82. | 0.7 | 0 |
| 33 | The combination of pharmacogenetic and pharmacokinetic analyses to optimize clomipramine dosing in major depression: a case report. <i>Journal of Clinical Pharmacy and Therapeutics</i> , 2017, 42, 119-121. | 0.7 | 0 |
| 34 | Genetic Factors Associated with Platinum Toxicity: A Preliminary Study. <i>Annals of Oncology</i> , 2017, 28, vi95. | 0.6 | 0 |